Real-world adverse events are rarely monocausal. They emerge from the interaction of drug exposure, comorbid conditions, physiological states, concomitant medications, and patient-specific ...
Unpack how rising competition for the same high-profile sites is slowing startup and enrollment—and what sponsors must change ...
In today’s ACT Brief, we hear how sponsors may redefine efficiency to protect patient access in 2026, review Verana Health’s ...
The merger enhances Verana Health's data capabilities across oncology, ophthalmology, urology, and neurology, supporting clinical research and regulatory decision-making. Integration of COTA's ...
Explore how sponsors can recalibrate efficiency efforts to avoid overconcentrating trials at familiar sites and instead ...
In today’s ACT Brief, we examine the growing challenges of sourcing comparator drugs across the EU, highlight a new AI-driven ...
BostonGene has entered a new collaboration with AstraZeneca to apply its foundation AI model to oncology drug development, aiming to improve early trial decision-making around safety, efficacy, and ...
Securing comparator drugs in the EU is a complex process shaped by availability constraints, regulatory expectations, and competitive market behavior. But if we have the right planning, strong ...
In today’s ACT Brief, we examine why representative enrollment remains a barrier in US cancer trials, review Johnson & ...
The JASMINE trial showed nipocalimab's efficacy in SLE, meeting primary and secondary endpoints, including steroid sparing ...
So having a representative population is really important. One part of that is being able to enroll more patients in the ...
In today’s ACT Brief, we explore how site initiation can be leveraged to improve early trial performance through demonstrated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback